CN108358842A

CN108358842A - His quinoline not crystal form of moral and preparation method thereof, its pharmaceutical composition and purposes

Info

Publication number: CN108358842A
Application number: CN201810340855.7A
Authority: CN
Inventors: 朱涛; 盛晓红; 盛晓霞
Original assignee: HANGZHOU PUSHA PHARMACEUTICAL TECHNOLOGY Co Ltd
Current assignee: Hangzhou Ling Ye Pharmaceutical Technology Co., Ltd
Priority date: 2014-08-28
Filing date: 2014-08-28
Publication date: 2018-08-03
Also published as: CN105367492B; CN105367492A

Abstract

The present invention relates to the novel crystal forms of his quinoline not moral, compared with solid-state form known to his quinoline not moral, novel crystal forms of the invention have advantage in crystallinity, stability, hygroscopicity, purity etc..The invention further relates to the preparation method of the novel crystal forms, its pharmaceutical composition and its purposes in preparing the drug for treating and/or preventing malignant tumour and autoimmune disease.

Description

His quinoline not crystal form of moral and preparation method thereof, its pharmaceutical composition and purposes

The application is that August in 2014 submits Patent Office of the People's Republic of China on 28th, and application No. is 201410428845.0 patent applications The divisional application of " his quinoline not crystal form of moral and preparation method thereof, its pharmaceutical composition and purposes ".

Technical field

The present invention relates to pharmaceutical chemistry crystallization technique fields.In particular to his the quinoline not crystal form of moral and its preparation Method, pharmaceutical composition and purposes.

Background technology

Entity tumor, primary or metastatic tumour be made of several cells, tumour cell therein has been central role Cell, and nutrition cannot be met by general diffusion when micro- tumour reaches certain size with driving force It needs, new blood vessel is inserted into tumour, forms microenvironment, and best nutrition is provided for the further proliferation of tumour and growth.It is this Angiogenesis caused by tumour, hyperplasia, migration and the differentiation for including the normal endothelial cell from neighbouring minute blood vessel are real The prerequisite of body tumour growth correspondingly inhibits angiogenesis that can effectively inhibit the growth of entity tumor.

Entity tumor penetrates organization edge and spreads, and generates daughter cell group or migration tumor.Single tumor cell and small Cell aggregate is diffused into remote position by blood or lymphatic system, and in this course, tumour cell is fragile, energy Enough to be eliminated by natural killer (NK) cell, which is a kind of abnormal shape of cytotoxic lymphocyte.Enhance NK cell activity Or increase the transition process that its number can reduce or inhibit solid tumor disease.

His quinoline not moral (English name Tasquinimod also known as ABR-215050), is to enliven the limited public affairs of biotechnology A kind of new small molecule inhibitors that (Active Biotech) is directed to tumor microenvironment development are taken charge of, has and inhibits tumor vessel It generates and antitumor action, preclinical research finds there is preferable efficacy and saferry to prostate cancer, enters face at present The bed III phases test.Moral not can be used for inhibiting the development of Several Kinds of Malignancy especially angiogenesis type entity tumor for his quinoline, also It can be used for treating autoimmune disease and pathology inflammatory disease.

Moral does not belong to N- alkyl-N- phenyl-quinolin -3- carboxyl acylamide derivatives to his quinoline, and chemical name is 4- hydroxyls -5- Methoxyl group-N, 1- dimethyl -2- oxos-N- [(4- trifluoromethyls) phenyl] -1,2- dihydroquinoline -3- formamides, chemistry knot Structure formula is as follows：

Patent document WO2000/003991A1 discloses his quinoline not moral and preparation method thereof, it is said that wherein embodiment 8 The crystalline deposit of his quinoline not moral has been arrived, and has disclosed it¹HNMR and¹³CNMR data.The present inventor repeats the patent document method " crystalline deposit " described in document has been obtained, has confirmed that it is that appearance is similar to be somebody's turn to do " crystalline deposit " through polarization microscope (PLM) detection The glassy solids of amorphous material confirm through X-ray powder diffraction (XRPD) characterization and are somebody's turn to do " crystalline deposit " salt free ligands peak, are nothing Sizing object.

Patent document WO2012/004338A1 reports some derivatives of N- alkyl-N- phenyl-quinolin -3- carboxylic acid amides And preparation method thereof, including his quinoline not moral.The present inventor is the study found that be prepared according to WO2012/004338Al Moral is not amorphous article to his quinoline yet, has the shortcomings that purity is low, thermal stability is poor and easy to moisture absorption.

Deficiency is remained in view of the prior art, and there is still a need for his quinolines that exploitation has more crystalline states for improving performances for this field Mo De, in the form of meeting pharmaceutical preparation for active material, the strict demand of the physico-chemical properties such as purity.

Invention content

It is of the existing technology to solve the problems, such as it is an object of the present invention to provide the novel crystal forms of his quinoline not moral.The novel crystal forms For stable crystalline solid, there should be one or more improved characteristics, especially in crystallinity, purity, hygroscopicity, preparation Machinability, stability etc..Moreover, it relates to the preparation method of the novel crystal forms, include the novel crystal forms Medical composition and its use.

According to the object of the invention, the present invention provides structural formula his quinoline as follows not moral crystal form I (for convenience, this hair It is called in bright " crystal form I ")：

It is radiated using Cu-K α, the crystal form I has following characteristics peak with the X-ray powder diffraction figure that 2 θ angles indicate： 8.2 ± 0.2 °, 11.3 ± 0.2 °, 16.2 ± 0.2 °, 18.6 ± 0.2 °, 23.0 ± 0.2 ° and 23.7 ± 0.2 °.

In a currently preferred embodiment, X-ray powder diffraction figure that the crystal form I is indicated with 2 θ angles With following characteristics peak：8.2±0.2°、10.1±0.2°、11.3±0.2°、11.7±0.2°、14.3±0.2°、 16.2± 0.2 °, 16.5 ± 0.2 °, 16.9 ± 0.2 °, 17.8 ± 0.2 °, 18.6 ± 0.2 °, 23.0 ± 0.2 ° and 23.7 ± 0.2 °.

In an embodiment of the invention further preferred, X- ray powders that the crystal form I is indicated with 2 θ angles Diffraction pattern has following characteristics peak and its relative intensity：

Without limitation, a representative instance of the crystal form I has XRPD collection of illustrative plates as shown in Figure 5.

The crystal form I has at least one following characteristic：

The PLM collection of illustrative plates of the crystal form I is shown as granular crystals；

The TGA collection of illustrative plates of the crystal form I is shown：The weightlessness about 0.05% before 100 DEG C illustrates that crystal form I is anhydride；Point It is about 166.5 DEG C to solve temperature；

The DSC collection of illustrative plates of the crystal form I is shown：There are one endothermic peaks between 190 DEG C~220 DEG C；

The adsorption isothermal curve of the crystal form I is shown：Weight change in 20%~80% RH range is about 0.06%, illustrate that crystal form I is not easy to moisture absorption.

Compared with his quinoline of the prior art not moral amorphous article, crystal form I of the invention has following beneficial property：

1) by XRPD collection of illustrative plates and PLM collection of illustrative plates it is found that crystal form I is crystalline solid, crystallinity is high；

2) by DSC collection of illustrative plates and TGA collection of illustrative plates it is found that his quinoline moral amorphous article can not occur to turn crystalline substance at 100 DEG C or so；And it is brilliant The decomposition temperature of type I is high, and thermal stability is good；

3) by adsorption isothermal curve it is found that crystal form I has hygroscopicity more lower than amorphous article；

4) using his quinoline crystalline substance that moral amorphous article is not prepared as raw material (its HPLC purity about 96.0%) of the prior art There is type I higher purity, HPLC purity to be at least 99.0%；

5) tested by competitiveness in water, illustrate his quinoline of the present invention not moral crystal form I not than his known quinoline moral without Object of shaping has better stability.

Above-mentioned beneficial property shows：Compared with his quinoline of the prior art not moral amorphous article, crystal form I has a variety of advantages Performance is more suitable for the active constituent of pharmaceutical preparation.Amorphous article is unstable, is easily influenced that crystal form turn occurs by foeign element Change, and then influences the quality and stability of preparation, and crystal form I is crystalline solid, stability of crystal form is substantially better than unformed Object.Crystalline solid have better mobility and more excellent following process (filtering, drying in such as pharmaceutical manufacturing process, The operations such as weighing, sieving) characteristic, be conducive to improve preparation homogeneity.Crystal form I is more stable in water, is more suitable for wet granulation. Crystal form I has higher purity, can reduce the issuable undesirable poisonous effect of impurity.Crystal form I has preferably hot steady Qualitative and lower hygroscopicity can preferably fight drug manufacture and/or storage etc. in the process by environment temperature, humidity etc. The problems such as active component content caused by factor is uneven, impurity increases, preparation machinability reduces, what thus reduction was brought Curative effect downside risk and security risk, and facilitate the storage and transport in later stage.

The preparation method of his quinoline not moral crystal form I, using any one in following preparation methods (1)~(4)：

(1) by his quinoline, moral does not form suspension in solvent, wherein the solvent is selected from water, normal propyl alcohol, n-butanol, 1, 4- dioxane, tetrahydrofuran, C₃~C₅Ketone or C₃~C₅Ester, stirring and crystallizing obtain his quinoline not moral crystal form I.

Preferably, the solvent is selected from water, normal propyl alcohol, n-butanol, Isosorbide-5-Nitrae-dioxane, tetrahydrofuran, acetone, butanone Or ethyl acetate.

Preferably, the operation temperature of the preparation method (1) is -10 DEG C~60 DEG C；More preferably 10 DEG C~50 DEG C.

Preferably, the time of the crystallization is 1~3 day.

Preferably, the w/v of moral and solvent is not 10mg to his quinoline:1mL~50mg:1mL；More preferably 25mg:1mL~50mg:1mL.

By his quinoline, moral does not form solution in solvent at (2) 60 DEG C~70 DEG C, solution is cooled to -10 DEG C~10 DEG C, analysis Go out crystal, his quinoline not moral crystal form I is obtained, wherein the solvent is selected from normal propyl alcohol, n-butanol, C₃~C₅Ketone or C₃~C₅Ester.

Preferably, the solvent is selected from normal propyl alcohol, n-butanol, acetone, butanone or ethyl acetate.

Preferably, the rate of the cooling is 2 DEG C/h~30 DEG C/h；More preferably 10 DEG C/h~20 DEG C/small When.

Preferably, a concentration of 25mg/mL~100mg/mL of described 60 DEG C~70 DEG C of his quinoline not moral solution；More preferably For 25mg/mL~50mg/mL.

(3) by his quinoline, moral does not form solution in solvent, anti-solvent is added, stirring and crystallizing, obtaining his quinoline, moral is not brilliant Type I, wherein the solvent is selected from methanol, chloroform, acetonitrile, C₃~C₅Ketone or C₃~C₅Ester, the anti-solvent are selected from water or C₆~C₈ Linear paraffin.

Preferably, the solvent is selected from methanol, chloroform, acetonitrile, acetone, butanone, ethyl acetate or isopropyl acetate.

Preferably, the anti-solvent is selected from water or normal heptane.

Preferably, the anti-solvent and the volume ratio of solvent are 3:1~10:1；More preferably 5:1~10:1.

Preferably, a concentration of 7.5mg/mL~75mg/mL of his quinoline not moral solution；More preferably 30mg/mL~ 75mg/mL。

Preferably, the operation temperature of the preparation method (3) is room temperature.

Preferably, the time of the crystallization is 0.5 hour~3 hours.

(4) by the solution evaporation of his quinoline not moral to dry, wherein the solvent of the solution is selected from normal propyl alcohol, Isosorbide-5-Nitrae-dioxy six Ring, C₃~C₅Ketone or C₃~C₅Ester obtains his quinoline not moral crystal form I.

Preferably, the solvent is selected from normal propyl alcohol, Isosorbide-5-Nitrae-dioxane, acetone or ethyl acetate.

Preferably, the operation temperature of the preparation method (4) is 10 DEG C~60 DEG C；More preferably room temperature.

His above-mentioned quinoline is not in preparation method (1)~(4) of moral crystal form I, the C₃~C₅Ketone can be acetone, butanone, 2- Pentanone or propione, the C₃~C₅Ester can be Ethyl formate, methyl acetate, ethyl acetate, propyl formate, methyl propionate, Isopropyl formate, isopropyl acid methyl esters, propyl acetate, isopropyl acetate, ethyl propionate or isopropyl acetoacetic ester, the C₆~C₈Straight chain Alkane can be n-hexane, normal heptane, normal octane.

His above-mentioned quinoline is in preparation method (1)~(4) of moral crystal form I, and moral is not known for starting material his quinoline, such as (glassy solids of similar crystalline state are not without fixed to moral to his quinoline prepared with reference to patent document WO2000/003991A1 embodiments 8 Type object) or his quinoline for preparing with reference to patent document WO2012/004338Al embodiments 4 not moral.

According to the object of the invention, the present invention also provides structural formula his quinoline as follows not moral alcohol solvent compound (in order to It is convenient, be called " alcohol solvent compound " in the present invention)：

It is radiated using Cu-K α, the alcohol solvent compound has following with the X-ray powder diffraction figure that 2 θ angles indicate Characteristic peak：6.9 ± 0.2 °, 10.6 ± 0.2 °, 12.1 ± 0.2 °, 17.1 ± 0.2 °, 17.7 ± 0.2 ° and 21.2 ± 0.2 °.

In a currently preferred embodiment, X-ray powder that the alcohol solvent compound is indicated with 2 θ angles Last diffraction pattern has following characteristics peak：6.9±0.2°、9.9±0.2°、10.6±0.2°、12.1±0.2°、12.8±0.2°、 16.3 ± 0.2 °, 17.1 ± 0.2 °, 17.7 ± 0.2 °, 19.4 ± 0.2 °, 21.2 ± 0.2 °, 22.6 ± 0.2 ° and 24.4 ± 0.2°。

In an embodiment of the invention further preferred, X- that the alcohol solvent compound is indicated with 2 θ angles Ray powder diffraction pattern has following characteristics peak and its relative intensity：

Without limitation, a representative instance of the alcohol solvent compound has XRPD collection of illustrative plates as shown in Figure 10.

The alcohol solvent compound has at least one following characteristic：

The PLM collection of illustrative plates of the alcohol solvent compound is shown as granular crystals；

The DSC collection of illustrative plates of the alcohol solvent compound is shown：At 100~120 DEG C and 180~210 DEG C, respectively there are one heat absorptions Peak；

The TGA collection of illustrative plates of the alcohol solvent compound is shown：Before 150 DEG C, it is about 9.0% to have a step weightlessness, is roughly equal to One moles ethanol solvate contains a moles ethanol, thus speculate the alcohol solvent compound be his quinoline not moral and ethyl alcohol with About 1:The compound that 1 molar ratio is formed；

The adsorption isothermal curve of the alcohol solvent compound is shown in the change of the weight in 20%~80% RH range Change about 0.98%, illustrates that alcohol solvent compound is not easy to moisture absorption.

Compared with his quinoline of the prior art not moral amorphous article, alcohol solvent compound of the invention has following helpfulness Matter：

1) by XRPD collection of illustrative plates and PLM collection of illustrative plates it is found that alcohol solvent compound is crystalline solid, crystallinity is high；

2) by DSC collection of illustrative plates and TGA collection of illustrative plates it is found that his quinoline moral amorphous article can not occur to turn crystalline substance at 100 DEG C or so；And second The decomposition temperature of solvate is high, and thermal stability is good；

3) by adsorption isothermal curve it is found that alcohol solvent compound has the lower hygroscopicity of moral amorphous article not than his quinoline；

4) using his quinoline second that moral amorphous article is not prepared as raw material (its HPLC purity about 96.0%) of the prior art There is solvate higher purity, HPLC purity to be at least 99.0%；

5) by the way that in the mixed solvent of water or water and ethyl alcohol, (volume ratio of water and ethyl alcohol is 1:1~1:4) competitiveness in Experiment illustrates that than his known quinoline moral amorphous article does not have and preferably stablizes moral alcohol solvent compound for his quinoline of the present invention Property.

Above-mentioned beneficial property shows：Compared with his quinoline of the prior art not moral amorphous article, alcohol solvent of the invention Object has a variety of advantage performances, is more suitable for the active constituent of pharmaceutical preparation.Amorphous article is unstable, easily by foeign element It influences that transformation of crystal occurs, and then influences the quality and stability of preparation, and alcohol solvent compound is crystalline solid, crystal form Stability is substantially better than amorphous article.Crystalline solid has better mobility and more excellent following process (such as drug system The operations such as filter, dry, weighing, being sieved during making) characteristic, be conducive to improve preparation homogeneity.Alcohol solvent compound exists It is more stable in Aquo System, it is more suitable for wet granulation.Alcohol solvent compound has higher purity, it is possible to reduce impurity may The undesirable poisonous effect generated.Alcohol solvent compound has better thermal stability and lower hygroscopicity, Neng Gougeng The active component content caused by the factors such as environment temperature, humidity is uneven during fighting drug manufacture and/or storage etc. well The problems such as even, impurity increases, preparation machinability reduces reduces the effect of thus bringing downside risk and security risk, and square The storage and transport of phase after an action of the bowels.

The preparation method of the alcohol solvent compound, using any one in following preparation methods (1)~(6)：

The ethanol solution that his quinoline not moral is formed at (1) 50 DEG C~70 DEG C, is cooled to -10 DEG C~10 DEG C by solution, is precipitated brilliant Body obtains his quinoline not moral alcohol solvent compound.

Preferably, the rate of the cooling is 2 DEG C/h~10 DEG C/h.

Preferably, a concentration of 40mg/mL~80mg/mL of described 50 DEG C~70 DEG C of his quinoline not moral ethanol solution.

(2) ethanol solution of his quinoline not moral is evaporated into dry, obtains his quinoline not moral alcohol solvent compound.

Preferably, the operation temperature of the preparation method (2) is room temperature.

(3) by his quinoline, moral is not dissolved in ethyl alcohol and forms solution, is added and is selected from water or C₆~C₈The anti-solvent of linear paraffin, Stirring and crystallizing obtains his quinoline not moral alcohol solvent compound.

Preferably, the anti-solvent is water or normal heptane.

Preferably, the volume ratio of the ethyl alcohol and anti-solvent is 1:1~1:4.

Preferably, the time of the stirring and crystallizing is 0.5~10 hour.

Preferably, a concentration of 12.5mg/mL~25mg/mL of his quinoline not ethanol solution of moral.

The C₆~C₈Linear paraffin can be n-hexane, normal heptane, normal octane.

(4) by his quinoline, moral does not form suspension in ethyl alcohol, stirring and crystallizing, obtains his quinoline not moral alcohol solvent Object.

Preferably, the operation temperature of the preparation method (4) is room temperature.

Preferably, the time of the stirring and crystallizing is 1 day~3 days.

Preferably, the w/v of moral and ethyl alcohol is not 50mg to his quinoline:1mL~80mg:1mL.

(5) it to the not German-Chinese addition ethyl alcohol of his quinoline, is ground to dry, obtains his quinoline not moral alcohol solvent compound.

Preferably, the w/v of moral and ethyl alcohol is not 75mg to his quinoline:1mL~100mg:1mL.

Preferably, the operation temperature of the preparation method (5) is room temperature.

The operation of " grinding " is for example：Sample is placed in agate mortar and adds the appropriate conventional grinding of solvent progress.

(6) by his quinoline, moral is not statically placed in the closed environment full of alcohol gas, obtains his quinoline not moral alcohol solvent Compound.

Preferably, the time of the standing is 1~3 day.

Preferably, the operation temperature of the preparation method (6) is room temperature.

The mode of operation of preparation method (6) is for example：In the bulk container equipped with ethyl alcohol, it is put into equipped with the small of his quinoline not moral Container, small container is open, bulk container sealing.

His above-mentioned quinoline is in preparation method (1)~(6) of moral alcohol solvent compound, and moral can not be for starting material his quinoline It is known, his quinoline prepared referring for example to patent document WO2000/003991A1 embodiments 8 the not moral (glassy state of similar crystalline state Solid is amorphous article) or his quinoline for preparing with reference to patent document WO2012/004338Al embodiments 4 not moral；Or starting Raw material his quinoline not moral can also be the present invention his quinoline not moral crystal form I.

According to the object of the invention, the present invention also provides his quinoline not moral Isosorbide-5-Nitrae-dioxane solvent compound A.Without limitation, A representative instance of his quinoline not moral 1,4- dioxane solvents compound A has the XRPD collection of illustrative plates as shown in Figure 15.

The preparation method of his quinoline not moral Isosorbide-5-Nitrae-dioxane solvent compound A, includes the following steps：By his quinoline not moral Isosorbide-5-Nitrae-dioxane solution cool down crystallization, his quinoline not moral Isosorbide-5-Nitrae-dioxane solvent compound A is obtained, wherein the drop Temperature is to be down to 10 DEG C from 60 DEG C, and the rate of cooling is 20 DEG C/h~30 DEG C/h, and Isosorbide-5-Nitrae-dioxane of his quinoline not moral is molten The initial concentration of liquid is 10mg/mL~30mg/mL.

According to the object of the invention, the present invention also provides his quinoline not moral Isosorbide-5-Nitrae-dioxane solvent compound B.Without limitation, A representative instance of his quinoline not moral 1,4- dioxane solvents compound B has the XRPD collection of illustrative plates as shown in Figure 16.

The preparation method of his quinoline not moral Isosorbide-5-Nitrae-dioxane solvent compound B, includes the following steps：By his quinoline not moral Isosorbide-5-Nitrae-dioxane solution cool down crystallization, his quinoline not moral Isosorbide-5-Nitrae-dioxane solvent compound B is obtained, wherein the drop Temperature is to be down to 10 DEG C from 60 DEG C, and the rate of cooling is 2 DEG C/h~10 DEG C/h, and Isosorbide-5-Nitrae-dioxane of his quinoline not moral is molten The initial concentration of liquid is 30mg/mL~50mg/mL.

According to the object of the invention, the present invention also provides his quinoline not moral tetrahydrofuran solvates.Without limitation, described One representative instance of his quinoline not moral tetrahydrofuran solvate has XRPD collection of illustrative plates as shown in figure 17.

The preparation method of his quinoline not moral tetrahydrofuran solvate, includes the following steps：By the tetrahydrochysene of his quinoline not moral Tetrahydrofuran solution cools down crystallization, obtains his quinoline not moral tetrahydrofuran solvate.Preferably, the cooling is dropped from 60 DEG C To 10 DEG C.Preferably, the rate of the cooling is 2 DEG C/h~30 DEG C/h.Preferably, the tetrahydrochysene of his quinoline not moral The initial concentration of tetrahydrofuran solution is 10mg/mL~50mg/mL.

According to the object of the invention, the present invention also provides his quinoline not Division A League Matches of Germany Football solvates.Without limitation, his quinoline A representative instance of Division A League Matches of Germany Football solvate does not have XRPD collection of illustrative plates as shown in figure 18.

The preparation method of his quinoline not Division A League Matches of Germany Football solvate, includes the following steps：By the methanol solution of his quinoline not moral Cool down crystallization, obtains his quinoline not Division A League Matches of Germany Football solvate.Preferably, the cooling is to be down to 10 DEG C from 60 DEG C.It is preferred that The rate on ground, the cooling is 2 DEG C/h~30 DEG C/h.Preferably, the starting of his quinoline not methanol solution of moral is dense Degree is 10mg/mL~50mg/mL.

According to the object of the invention, the present invention also provides his quinoline not moral isopropanol solvates.Without limitation, it is described he Quinoline not moral isopropanol solvate a representative instance have XRPD collection of illustrative plates as shown in figure 19.

The preparation method of his quinoline not moral isopropanol solvate, includes the following steps：By the isopropanol of his quinoline not moral Solution cools down crystallization, obtains his quinoline not moral isopropanol solvate.Preferably, the cooling is to be down to 10 DEG C from 60 DEG C. Preferably, the rate of the cooling is 2 DEG C/h~30 DEG C/h.Preferably, his quinoline not aqueous isopropanol of moral Initial concentration is 10mg/mL~50mg/mL.

According to the object of the invention, the present invention also provides his quinoline not Division A League Matches of Germany Football solvate A.Without limitation, his quinoline A representative instance of Division A League Matches of Germany Football solvate A does not have XRPD collection of illustrative plates as shown in figure 20.

The preparation method of his quinoline not Division A League Matches of Germany Football solvate A, includes the following steps：The toluene of his quinoline not moral is molten Liquid cooling crystallization, obtaining his quinoline, Division A League Matches of Germany Football solvate A does not cool down wherein the cooling is to be down to -10 DEG C from 70 DEG C Rate be 2 DEG C/h~10 DEG C/h, the initial concentration of his quinoline not toluene solution of moral is 10mg/mL~25mg/mL.

According to the object of the invention, the present invention also provides his quinoline not Division A League Matches of Germany Football solvate B.Without limitation, his quinoline A representative instance of Division A League Matches of Germany Football solvate B does not have XRPD collection of illustrative plates as shown in figure 21.

The preparation method of his quinoline not Division A League Matches of Germany Football solvate B, includes the following steps：The toluene of his quinoline not moral is molten Liquid cooling crystallization, obtaining his quinoline, Division A League Matches of Germany Football solvate B does not cool down wherein the cooling is to be down to -10 DEG C from 70 DEG C Rate be 20 DEG C/h~30 DEG C/h, the initial concentration of his quinoline not toluene solution of moral is 30mg/mL~50mg/mL.

Compared with his quinoline of the prior art not moral amorphous article, Isosorbide-5-Nitrae-dioxane solvent of the present invention his quinoline not moral Object A, 1,4- dioxane solvent compound B, tetrahydrofuran solvate, Methanol Solvate, isopropanol solvate, toluene Solvate A or toluene solvate B all have beneficial property below：

1) by XRPD collection of illustrative plates it is found that above-mentioned solvate is crystalline solid, crystallinity is high；

2) by his quinoline of the prior art, to be that raw material (its HPLC purity about 96.0%) is prepared not upper for moral amorphous article It states solvate and all has higher purity, HPLC purity is above 98.0%；Especially form his quinoline not Division A League Matches of Germany Football alcoholic solvent The purification effect of compound or his quinoline not moral isopropanol solvate becomes apparent, and HPLC purity is above 99.5%.

Above-mentioned beneficial property shows：Compared with his quinoline of the prior art not moral amorphous article, the present invention his quinoline not moral 1, 4- dioxane solvent compound A, 1,4- dioxane solvent compounds B, tetrahydrofuran solvate, Methanol Solvate, isopropyl Solvate, toluene solvate A or toluene solvate B have a variety of advantage performances, are more suitable for pharmaceutical preparation Active constituent.Amorphous article is unstable, is easily influenced that transformation of crystal occurs by foeign element, and then influences the quality of preparation and steady It is qualitative, and above-mentioned solvate is crystalline solid, crystal form thermal stability is substantially better than amorphous article, can preferably fight The active component content caused by environment temperature, humidity etc. is uneven during drug manufacture and/or storage etc., impurity increases, The problems such as preparation machinability reduces reduces the effect of thus bringing downside risk and security risk, and facilitates the storage in later stage It deposits and transports.Crystalline solid has better mobility and the more excellent following process (mistake in such as pharmaceutical manufacturing process The operations such as filter, dry, weighing, sieving) characteristic, be conducive to the homogeneity for improving preparation.Above-mentioned solvate has higher pure Degree, it is possible to reduce the issuable undesirable poisonous effect of impurity.

The present invention his quinoline is not in the preparation method of the novel crystal forms of moral：

The stirring means of this field routine may be used in " stirring ", such as agitating mode includes magnetic agitation, machinery Stirring, mixing speed are 50~1800 revs/min, preferably 300~900 revs/min.

The novel crystal forms of his quinoline that crystallization obtains not moral, the conventional method that this field can be used are detached and are dried.It is described " separation ", such as filtering or centrifugation, preferably at room temperature to be filtered less than the pressure of atmospheric pressure, general pressure is less than 0.09MPa." drying ", such as air drying, forced air drying or be dried under reduced pressure, it is dried in draught cupboard, convection oven or vacuum It is carried out in case；It can depressurize or not depressurize, preferably pressure is less than 0.09MPa.Drying temperature is 10~40 DEG C, and drying time is 10~72 hours, preferably 2~24 hours, more preferably 2~8 hours.

The crystallization mode that the present invention uses includes volatilization crystallization, magma crystallization, crystallisation by cooling and antisolvent crystallization.

" volatilization " refers to that opening carries out volatilization crystallization at the corresponding temperature by the reaction bulb equipped with sample solution.

" magma " refers to the supersaturated solution (with the presence of insoluble solids, i.e. suspension) by sample in specific solvent Stirred crystallization under system, specific temperature.

" crystallisation by cooling " refers to by sample solution under relevant temperature according to certain cooling rate decrease temperature crystalline.

" antisolvent crystallization " refers to that a certain amount of anti-solvent is added in sample solution, solid is precipitated and is tied It is brilliant.Wherein anti-solvent refers to sample slightly soluble or largely insoluble solvent.

It is described " room temperature " in the present invention, refer to 10~30 DEG C.

It is described " anhydride " in the present invention, refer to measuring containing not more than 1.5% (weight ratio) or being not more than through TGA The sample of the water of 1.0% (weight ratio).

In the present invention, " crystal form " refers to being confirmed by shown X-ray powder diffraction figure characterization.Those skilled in the art Known, experimental error therein depends on instrument condition, preparation of samples and sample purity.Collection of illustrative plates would generally be with instrument condition And it changes.The relative intensity at peak may change with experiment condition, so the sequence of peak intensity cannot function as unique or determine Qualitative factor；The experimental error of peak angle degree should also be considered into, allow generally for ± 0.2 ° of error；Height of specimen etc. because The influence of element can cause peak angle degree overall offset, allow generally for certain offset.Thus, it will be appreciated by those skilled in the art that , any model that there is the crystal form with the same or similar characteristic peak of X-ray powder diffraction pattern of the present invention to belong to the present invention Farmland." single crystal form " refers to being detected as single crystal form through X-ray powder diffraction.

The novel crystal forms of his quinoline of the present invention not moral are pure, single, do not mix any other crystal form or amorphous substantially State." do not have substantially " when being used to refer to novel crystal forms in the present invention, refers to other crystal forms contained in this novel crystal forms or amorphous state is few In 20% (weight), more refer to less than 10% (weight), be especially less than 5% (weight), particularly relates to be less than 1% (weight)；Institute It states the novel crystal forms of his quinoline of the present invention not moral, includes crystal form I, alcohol solvent compound, the Isosorbide-5-Nitrae-dioxane solvent of his quinoline not moral Compound A, 1,4- dioxane solvent compound B, tetrahydrofuran solvate, Methanol Solvate, isopropanol solvate, first Solvate A and toluene solvate B.

According to the object of the invention, the present invention provides a kind of pharmaceutical composition, described pharmaceutical composition include treatment and/or The active constituents of medicine of prevention effective dose is selected from his quinoline of the present invention and the novel crystal forms of moral or is not obtained by preparation method of the present invention His quinoline not moral novel crystal forms, and at least one pharmaceutically acceptable carrier or auxiliary agent；His quinoline of the present invention not moral Novel crystal forms, include crystal form I, alcohol solvent compound, Isosorbide-5-Nitrae-dioxane solvent compound A, the Isosorbide-5-Nitrae-dioxane of his quinoline not moral Solvate B, tetrahydrofuran solvate, Methanol Solvate, isopropanol solvate, toluene solvate A and toluene are molten Agent compound B.In addition, described pharmaceutical composition can also include his quinoline not other crystal forms of moral or its officinal salt or without fixed Type object.Optionally, described pharmaceutical composition can also include one or more other active constituents of medicine.

It is preferred that conventional pharmaceutical composition is made according to conventional administration route in described pharmaceutical composition.Administration route packet Include it is oral, by stomach feeding tube, by duodenum feeding tube, intravenous, intra-arterial, intramuscular, subcutaneous, bone, skin In interior, intravaginal, rectum, peritonaeum is interior, transdermal, intranasal, eye drop, ear drop etc..Described pharmaceutical composition can be solid-state or liquid, Such as solid oral dosage form, including tablet, capsule, granule, pastille, powder, pill, pulvis, can be it is conventional, can Dispersion, masticable, Orally dissolving or rapid melting preparation；Liquid oral dosage form, including it is solution, syrup, mixed Suspension and emulsion；The sterile packaged powders that can be compounded before injectable formulation, including aseptic injectable solution, injection；The gas of sucking Mist agent；Rectally suppository or suitable topical formulations.Formula may be adapted to the quick-release, sustained release or controlled release of active constituent.It is preferred that Ground, described pharmaceutical composition are peroral dosage form, including tablet, capsule, granule, pastille, powder, pill, pulvis, solution Agent, syrup, suspension and emulsion.

Acceptable carrier or auxiliary agent are well known to those skilled in the art in described pharmaceutical composition Chinese pharmacology, can be had There are various well known forms, such as includes but not limited to：Diluent, for example, starch, modified starch, lactose, powdered cellulose, Microcrystalline cellulose, calcium phosphate dibasic anhydrous, tricalcium phosphate, mannitol, sorbierite, sugar etc.；Adhesive, such as Arabic gum, Guar Glue, gelatin, polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol, copolyvidone etc.；It collapses Solve agent, such as starch, sodium carboxymethyl starch, sodium starch glycollate, pregelatinized starch, crospovidone, cross-linked carboxymethyl fibre The plain sodium of dimension, colloidal silicon dioxide etc.；Lubricant, such as stearic acid, magnesium stearate, zinc stearate, sodium benzoate, sodium acetate Deng；Glidant, such as colloidal silicon dioxide etc.；Complex forming agents, for example, various ranks cyclodextrin and resin；Release speed Spend controlling agent, such as hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, Methyl cellulose Element, methyl methacrylate, wax etc..Other available pharmaceutically acceptable carriers or auxiliary agent include but not limited to film forming agent, Plasticizer, colorant, flavoring agent, viscosity modifier, preservative, antioxidant etc..It is usually used in the case of oral tablet Carrier include lactose and cornstarch, lubricant such as magnesium stearate can also be added；It is useful in the case of oral capsule Carriers/diluents include lactose, height and low molecular poly and dried corn starch；In the case of gelatine capsule agent, Dust carrier or auxiliary agent such as lactose, starch, cellulose derivative, magnesium stearate, stearic acid and analog；When with suspension When oral medication, the active constituent is mixed with emulsifier and suspending agent；If desired, can be added certain sweeteners and/or Flavoring agent and/or colorant.Each carrier or auxiliary agent must be acceptable, can it is compatible with the other compositions in formula simultaneously And it is harmless for sufferer.

Described pharmaceutical composition can use well known to a person skilled in the art methods to prepare.Prepare pharmaceutical composition When, the novel crystal forms of moral do not mix his quinoline of the invention with one or more pharmaceutically acceptable carriers or auxiliary agent, optionally Ground is mixed with one or more other active constituents of medicine.Solid pharmaceutical preparation can be by the techniques such as directly mixing, pelletizing To prepare.

According to the object of the invention, the present invention provides his quinoline of the present invention not novel crystal forms of moral or by preparation side of the invention His quinoline that method obtains not moral novel crystal forms prepare it is scorching for treating and/or preventing tumor disease, autoimmune disease or pathology Purposes in the drug of property disease；The novel crystal forms of his quinoline of the present invention not moral, including the crystal form I of moral, ethyl alcohol is not molten for his quinoline Agent compound, 1,4- dioxane solvent compound A, 1,4- dioxane solvent compounds B, tetrahydrofuran solvate, methanol solvate Compound, isopropanol solvate, toluene solvate A and toluene solvate B.The tumor disease includes but not limited to breast Gland cancer, colon cancer, Kaposi's sarcoma, lung cancer, oophoroma, prostate cancer and cutaneum carcinoma；Autoimmune disease is by whole body Immune system attacks or directly attacks the disease of various body organs, they are by immune system error, by mediate protection function Caused by becoming attacker, the autoimmune disease includes but not limited to multiple sclerosis (MS), insulin-dependent glycosuria Sick (IDDM), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and psoriasis；It is described Pathology inflammatory disease such as asthma, atherosclerosis, apoplexy and Alzheimer's disease.

According to the object of the invention, the present invention provides a kind for the treatment of and/or prevents above-mentioned tumor disease, autoimmunity disease The method of disease or pathology inflammatory disease, the method includes giving the present invention of the patient of needs treatment and/or prevention effective dose His quinoline novel crystal forms of moral or combinations thereof or do not include the foregoing pharmaceutical compositions of the present invention his quinoline not novel crystal forms of moral；It is described The novel crystal forms of his quinoline of the present invention not moral include crystal form I, alcohol solvent compound, the Isosorbide-5-Nitrae-dioxane solvent of his quinoline not moral Object A, 1,4- dioxane solvent compound B, tetrahydrofuran solvate, Methanol Solvate, isopropanol solvate, toluene Solvate A and toluene solvate B.The patient is mammal including people.Suitable day agent for treating disease Ranging from 0.002mg/kg- about 100mg/kg weight, especially 0.02mg/kg-10mg/kg weight are measured, this is dependent on specific The reaction of the illness for the treatment of, the age of particular patient and weight and particular patient to drug therapy, accurate dosage will cure It is determined according to the medical principle of standard under teacher's guidance.

Description of the drawings

Fig. 1 is the XRPD collection of illustrative plates of his quinoline for being prepared with reference to WO2000/003991Al not moral

Fig. 2 is the PLM collection of illustrative plates of his quinoline for being prepared with reference to WO2000/003991Al not moral

Fig. 3 is the DSC collection of illustrative plates of his quinoline for being prepared with reference to WO2000/003991Al not moral

Fig. 4 is the adsorption isothermal curve of his quinoline for being prepared with reference to WO2000/003991Al not moral

Fig. 5 is the XRPD collection of illustrative plates of his quinoline not moral crystal form I of the present invention

Fig. 6 is the PLM collection of illustrative plates of his quinoline not moral crystal form I of the present invention

Fig. 7 is the DSC collection of illustrative plates of his quinoline not moral crystal form I of the present invention

Fig. 8 is the TGA collection of illustrative plates of his quinoline not moral crystal form I of the present invention

Fig. 9 is the adsorption isothermal curve of his quinoline not moral crystal form I of the present invention

Figure 10 is the XRPD collection of illustrative plates of his quinoline not moral alcohol solvent compound of the present invention

Figure 11 is the PLM collection of illustrative plates of his quinoline not moral alcohol solvent compound of the present invention

Figure 12 is the DSC collection of illustrative plates of his quinoline not moral alcohol solvent compound of the present invention

Figure 13 is the TGA collection of illustrative plates of his quinoline not moral alcohol solvent compound of the present invention

Figure 14 is the adsorption isothermal curve of his quinoline not moral alcohol solvent compound of the present invention

Figure 15 is the XRPD collection of illustrative plates of his quinoline not moral 1,4- dioxane solvents compound A of the present invention

Figure 16 is the XRPD collection of illustrative plates of his quinoline not moral 1,4- dioxane solvents compound B of the present invention

Figure 17 is the XRPD collection of illustrative plates of his quinoline not moral tetrahydrofuran solvate of the present invention

Figure 18 is the XRPD collection of illustrative plates of his quinoline not Division A League Matches of Germany Football solvate of the present invention

Figure 19 is the XRPD collection of illustrative plates of his quinoline not moral isopropanol solvate of the present invention

Figure 20 is the XRPD collection of illustrative plates of his quinoline not Division A League Matches of Germany Football solvate A of the present invention

Figure 21 is the XRPD collection of illustrative plates of his quinoline not Division A League Matches of Germany Football solvate B of the present invention

Specific implementation mode

It will be helpful to further understand the present invention by following embodiments, but be not used in limitation present disclosure.

Detecting instrument and method：

X-ray powder diffraction (XRPD)：Instrument is Bruker D8Advance diffractometer, using copper target Wavelength is the Ka X-rays of 1.54nm, under the operating condition of 40kV and 40mA, θ -2 θ angular instruments, Mo monochromators, Lynxeye Detector.Instrument is calibrated using preceding with diamond dust.Acquisition software is Diffrac Plus XRD Commander.Sample exists It tests under room temperature, sample is placed on areflexia plate.Detailed testing conditions are as follows, angular range：3~40 ° of 2 θ, step-length： 0.02 ° of 2 θ, speed：0.2 second/step.

Polarization microscope (PLM) collection of illustrative plates picks up from that (the rectangular optical instrument in Shanghai is limited in XP-500E polarization microscopes Company).It takes a small amount of powder sample to be placed on glass slide, a small amount of mineral oil is added dropwise to better disperse powder sample, close the lid glass Then sample is placed on the objective table of XP-500E polarization microscopes by piece, select suitable amplification factor observing samples Pattern and take pictures.

Differential thermal analysis (DSC)：Data are picked up from TA Instruments Q200MDSC, and instrument control software is Thermal Advantage, analysis software are Universal Analysis.1~10 milligram of sample is usually taken to be placed in aluminium dish It is interior, N is dried in 40mL/min with the heating rate of 10 DEG C/min₂Sample is risen to 250 DEG C from room temperature under protection.

Thermogravimetric analysis (TGA)：Data are picked up from TA Instruments Q500TGA, and instrument control software is Thermal Advantage, analysis software are Universal Analysis.The sample of 5~15mg is usually taken to be positioned in platinum crucible, By the way of being segmented high resolution detection, N is dried in 40mL/min with the heating rate of 10 DEG C/min₂Protection under by sample 250 DEG C are risen to from room temperature.

Adsorption isothermal curve (DVS)：Data are picked up from TA Instruments Q5000TGA, and instrument control software is Thermal Advantage, analysis software are Universal Analysis.The sample of 1~10mg is usually taken to be positioned over platinum In crucible, weight change of the TA software records sample in 0%~80% change procedure of relative humidity.According to the specific of sample Situation also can use different absorption and De contamination step to sample.

Nucleus magnetic hydrogen spectrum data (¹HNMR it) picks up from Bruker Avance II DMX 400MHZ nuclear magnetic resonance chemical analysers. 1-5mg samples are weighed, with 0.5mL deuterochloroforms (CDCl₃) dissolving, it is made into the solution of 2mg/mL-10mg/mL.

High performance liquid chromatography (HPLC)：Analysis data are picked up from Agilent 1260, B.04 chem workstation is.Accordingly Parameter is as follows：UsingC18 chromatographic columns, 5 μm of 4.6 × 250mm, 30 DEG C, flow velocity 1.0ml/min of column temperature, wavelength 265nm, 20 μ l of sample size and run time 30 minutes.Mobile phase A is water, and Mobile phase B is acetonitrile, and gradient condition is shown in Table 1.

1 HPLC gradient conditions of table

Various reagents used in embodiment are commercially available purchase unless otherwise instructed.

It is ambient operation unless otherwise instructed in embodiment.

" overnight " described in embodiment refers to the time that the step crosses over evening, does not during which have to observe reality positively Test phenomenon.This period can be 8~22 hours or 10~18 hours, typically 16 hours.

Preparation example 1The preparation (prior art) of his quinoline not moral

With reference to the method for WO2000/003991Al embodiments 8 his quinoline is prepared moral, concrete operations are not as follows：0.5 Hour in, to ice cooling 1,2- dihydro-4- hydroxy-5-methyls Oxy-1-methyl-2- oxo-quinoline-3- carboxylic acids (8g, 0.032mol), triethylamine (15.5mL, 0.11mol) and 4- trifluoromethyls-methylphenylamine (6.1g, 0.035mol) The 10mL dichloromethane solutions of thionyl chloride (3.0mL, 0.042mol) are added dropwise in 150mL dichloromethane solutions, 4 DEG C are continued to stir It mixes 4 hours, with 10mL dichloromethane dilute solutions, with cold 1M sulfuric acid scrubbings, then with 1M sodium hydroxide extractions, adjusts water phase PH to 8-8.5, filter out clarified solution, pH4 be then acidified to hydrochloric acid, filter out the precipitation placed and formed, with water washing and dry It is dry, obtain 8.5g his quinolines not moral.

Product¹H-NMR(CDCl₃) data are as follows：9.9 (s, 1H), 7.50 (bs, 4H), 7.46 (t, 1H), 6.94 (d, 1H), 6.70 (d, 1H), 4.06 (s, 3H), 3.54 (s, 3H), 3.48 (s, 3H).

Its XRPD collection of illustrative plates is amorphous article as shown in Figure 1, salt free ligands peak.

Its PLM collection of illustrative plates is as shown in Fig. 2, be the irregular block of no polarization light；Appearance is that the glassy state of similar crystalline state is solid Body.

Its DSC collection of illustrative plates is as shown in Figure 3：There is heat release and endothermic peak between 80 DEG C~110 DEG C.

Its adsorption isothermal curve is as shown in Figure 4：Weight change is 4.1% in 20%~80% RH range.

The above characterization result shows：Moral is not his quinoline obtained with reference to 8 preparation method of WO2000/003991Al embodiments Amorphous article can occur to turn crystalline substance at 100 DEG C or so, easy to moisture absorption.

Embodiment 1

His quinoline of 50mg preparation examples 1 not moral is taken, 2mL ethyl acetate is added to form suspension, 10 DEG C are stirred 3 days, filtering, and 40 DEG C forced air drying 2 hours obtains 44mg his quinolines not moral crystal form I, yield 88%.

Embodiment 2

His quinoline of 50mg preparation examples 1 not moral is taken, adds 1.5mL1,4- dioxane to form suspension, 25 DEG C are stirred 3 days, mistake Filter, 40 DEG C of forced air dryings 8 hours obtain 35mg his quinolines not moral crystal form I, yield 70%.

Embodiment 3

His quinoline of 50mg preparation examples 1 not moral is taken, adds 2mL normal propyl alcohols to form suspension, -10 DEG C are stirred 1 day, filtering, 40 DEG C Forced air drying 2 hours obtains 36mg his quinolines not moral crystal form I, yield 72%.

Embodiment 4

His quinoline of 50mg preparation examples 1 not moral is taken, adds 1mL n-butanols to form suspension, 50 DEG C are stirred 1 day, filtering, 40 DEG C Forced air drying 8 hours obtains 39mg his quinolines not moral crystal form I, yield 78%.

Embodiment 5

His quinoline of 50mg preparation examples 1 not moral is taken, adds 5mL water to form suspension, 60 DEG C are stirred 3 days, filtering, 40 DEG C of air blast Dry 4 hours, obtain 34mg his quinolines not moral crystal form I, yield 68%.

Embodiment 6

His quinoline of 50mg preparation examples 1 not moral is taken, 1mL tetrahydrofurans is added to form suspension, 10 DEG C are stirred 1 day, filtering, and 40 DEG C forced air drying 2 hours obtains 23mg his quinolines not moral crystal form I, yield 46%.

Embodiment 7

His quinoline of 50mg preparation examples 1 not moral is taken, adds 1mL acetone to form suspension, -10 DEG C are stirred 1 day, filtering, 40 DEG C of drums It air-dries dry 2 hours, obtains 33mg his quinolines not moral crystal form I, yield 66%.

Embodiment 8

His quinoline of 50mg preparation examples 1 not moral is taken, adds 1mL butanone to form suspension, -10 DEG C are stirred 1 day, filtering, 40 DEG C of drums It air-dries dry 4 hours, obtains 35mg his quinolines not moral crystal form I, yield 70%.

Embodiment 9

His quinoline of 500mg preparation examples 1 not moral is taken, adds 20mL normal propyl alcohols to be warming up to 60 DEG C of dissolved clarifications, with 10 DEG C of drops hourly Warm speed is down to 10 DEG C, precipitates crystal, filtering, 40 DEG C of forced air dryings 2 hours, obtains 420mg his quinolines not moral crystal form I, yield 84%.

XRPD collection of illustrative plates is as shown in Figure 5.

PLM collection of illustrative plates is as shown in fig. 6, be granular crystals.

DSC collection of illustrative plates is as shown in Figure 7：At 190~220 DEG C, there are one endothermic peaks.

TGA collection of illustrative plates is as shown in Figure 8：The weightlessness about 0.05% before 100 DEG C is anhydride；Decomposition temperature is about 166.5 ℃。

Adsorption isothermal curve is as shown in Figure 9：Weight change in 20%~80% RH range is about 0.06%, it is not easy to moisture absorption.

Embodiment 10

His quinoline of 100mg preparation examples 1 not moral is taken, 2.5mL n-butanols is added to be warming up to 70 DEG C of dissolved clarifications, it is hourly with 30 DEG C Cooling rate is down to 10 DEG C, precipitates crystal, filtering, 40 DEG C of forced air dryings 8 hours, obtains 66mg his quinolines not moral crystal form I, yield 66%.

Embodiment 11

His quinoline of 100mg preparation examples 1 not moral is taken, adds 1mL acetone to be warming up to 60 DEG C of dissolved clarifications, with 20 DEG C of coolings hourly Speed is down to -10 DEG C, precipitates crystal, filtering, 40 DEG C of forced air dryings 2 hours, obtains 63mg his quinolines not moral crystal form I, yield 63%.

Embodiment 12

His quinoline of 100mg preparation examples 1 not moral is taken, adds 1mL butanone to be warming up to 65 DEG C of dissolved clarifications, with 2 DEG C of coolings speed hourly Degree is down to 0 DEG C, precipitates crystal, and filters, 40 DEG C of forced air dryings 4 hours, obtains 71mg his quinolines not moral crystal form I, yield 71%.

Embodiment 13

His quinoline of 100mg preparation examples 1 not moral is taken, 2mL ethyl acetate is added to be warming up to 60 DEG C of dissolved clarifications, it is hourly with 10 DEG C Cooling rate is down to 10 DEG C, precipitates crystal, filtering, 40 DEG C of forced air dryings 2 hours, obtains 76mg his quinolines not moral crystal form I, yield 76%.

Embodiment 14

His quinoline of 15mg preparation examples 1 not moral is taken, adds 1mL methanol dissolved clarifications, 3mL water is added, white crystal is precipitated, stirring 2 is small When crystallization, filtering, 40 DEG C of forced air dryings 1 hour obtain 9mg his quinolines not moral crystal form I, yield 60%.

Embodiment 15

His quinoline of 15mg preparation examples 1 not moral is taken, adds 0.5mL acetone dissolved clarifications, 2mL water is added, white crystal, stirring 3 is precipitated Hour crystallization, filtering, 40 DEG C of forced air drying half an hour obtain 8mg his quinolines not moral crystal form I, yield 53%.

Embodiment 16

His quinoline of 75mg preparation examples 1 not moral is taken, adds 1mL acetonitrile dissolved clarifications, 5mL water is added, white crystal is precipitated, stirring 3 is small When crystallization, filtering, 40 DEG C of forced air drying half an hour obtain 52mg his quinolines not moral crystal form I, yield 69%.

Embodiment 17

His quinoline of 30mg preparation examples 1 not moral is taken, adds 1mL butanone dissolved clarifications, 3mL normal heptanes is added, white crystal is precipitated, stirs 0.5 hour crystallization is mixed, is filtered, 40 DEG C of forced air dryings 1 hour obtain 18mg his quinolines not moral crystal form I, yield 60%.

Embodiment 18

His quinoline of 75mg preparation examples 1 not moral is taken, adds 1mL chloroform dissolved clarifications, 10mL normal heptanes is added, white crystal is precipitated, stirs 0.5 hour crystallization is mixed, is filtered, 40 DEG C of forced air dryings 1 hour obtain 58mg his quinolines not moral crystal form I, yield 77%.

Embodiment 19

His quinoline of 15mg preparation examples 1 not moral is taken, adds 1mL ethyl acetate dissolved clarifications, 4mL n-hexanes is added, it is brilliant that white is precipitated Body, stirs 0.5 hour crystallization, filtering, 40 DEG C of forced air dryings 1 hour, obtains 9mg his quinolines not moral crystal form I, yield 60%.

Embodiment 20

His quinoline of 15mg preparation examples 1 not moral is taken, adds 2mL isopropyl acetate dissolved clarifications, 5mL normal octanes is added, it is brilliant that white is precipitated Body, stirs 0.5 hour crystallization, filtering, 40 DEG C of forced air dryings 1 hour, obtains 7mg his quinolines not moral crystal form I, yield 47%.

Embodiment 21

His quinoline of 50mg preparation examples 1 not moral is taken, 60 DEG C plus 2mL1, the dissolving of 4- dioxane is placed in 60 DEG C of volatilization crystallizations, Volatilize after dry solvent to obtain 48mg his quinolines not moral crystal form I, yield 96%.

Embodiment 22

His quinoline of 50mg preparation examples 1 not moral is taken, 10mL normal propyl alcohols is added to dissolve, room temperature volatilization crystallization, after the dry solvent that volatilizees 46mg his quinolines not moral crystal form I, yield 92%.

Embodiment 23

His quinoline of 30mg preparation examples 1 not moral is taken, adds 2mL acetone solutions, room temperature volatilization crystallization, after the dry solvent that volatilizees 26mg his quinolines not moral crystal form I, yield 87%.

Embodiment 24

His quinoline of 30mg preparation examples 1 not moral is taken, 5mL ethyl acetate is added to dissolve, room temperature volatilization crystallization, after the dry solvent that volatilizees 25mg his quinolines not moral crystal form I, yield 83%.

Examples 1 to 8 and 10~24 sample and 9 samples of embodiment that prepare have same or analogous XRPD collection of illustrative plates, PLM collection of illustrative plates, DSC collection of illustrative plates and TGA collection of illustrative plates (not shown).Illustrating Examples 1 to 8 and 10~24 sample and 9 sample of embodiment is Identical crystal form.

Embodiment 25

His quinoline of 800mg preparation examples 1 not moral is taken, adds 10mL ethyl alcohol, is warming up to 70 DEG C of stirring and dissolvings, per hour with 10 DEG C Cooling rate be down to 10 DEG C, precipitate crystal, filter, room temperature forced air drying 2 hours, obtain 755mg his quinolines not moral alcohol solvent Object, yield 85%.

XRPD collection of illustrative plates is as shown in Figure 10.

PLM collection of illustrative plates is as shown in figure 11, is shown as granular crystals.

DSC collection of illustrative plates is as shown in figure 12, and being shown in 100~120 DEG C and 180~210 DEG C, respectively there are one endothermic peaks.

TGA collection of illustrative plates is as shown in figure 13.It is shown in weightlessness about 9.0% before 150 DEG C, about his quinoline of unification mole not moral ethyl alcohol Solvate contains a moles ethanol.

Adsorption isothermal curve is as shown in figure 14, is shown in weight change in 20%~80% RH range and is 0.98%, it is not easy to moisture absorption.

Embodiment 26

His quinoline of 100mg preparation examples 1 not moral is taken, adds 2.5mL ethyl alcohol, is warming up to 50 DEG C of stirring and dissolvings, per hour with 2 DEG C Cooling rate be down to 10 DEG C, precipitate crystal, filter, room temperature forced air drying 1 hour, obtain 77mg his quinolines not moral alcohol solvent Object, yield 69%.

Embodiment 27

His quinoline of 120mg preparation examples 1 not moral is taken, adds 2mL ethyl alcohol, is warming up to 60 DEG C of stirring and dissolvings, it is hourly with 5 DEG C Cooling rate is down to -10 DEG C, precipitates crystal, filtering, room temperature forced air drying 1 hour, obtains 95mg his quinolines not moral alcohol solvent Object, yield 71%.

Embodiment 28

His quinoline of 50mg preparation examples 1 not moral is taken, 4mL ethyl alcohol is added to dissolve, the room temperature dry solvent that volatilizees obtains 52mg his quinolines not moral second Solvate, yield 93%.

Embodiment 29

His quinoline of 100mg preparation examples 1 not moral is taken, adds 4mL ethyl alcohol to dissolve, 32mL normal heptanes is slowly added under stirring, stir It 0.5 hour, precipitates crystal, filters, room temperature forced air drying 1 hour, obtaining 78mg his quinolines, moral alcohol solvent compound, yield are not 70%.

Embodiment 30

His quinoline of 100mg preparation examples 1 not moral is taken, adds 8mL ethyl alcohol to dissolve, 8mL water is slowly added under stirring, stirring 10 is small When, it precipitates crystal, filters, room temperature forced air drying 1 hour, obtain 66mg his quinolines not moral alcohol solvent compound, yield 59%.

Embodiment 31

His quinoline of 50mg preparation examples 1 not moral is taken, 1mL ethyl alcohol is added and forms suspension, at room temperature stirring and crystallizing 3 days, mistake Filter, room temperature forced air drying 1 hour obtain 46mg his quinolines not moral alcohol solvent compound, yield 83%.

Embodiment 32

His quinoline of 80mg preparation examples 1 not moral is taken, 1mL ethyl alcohol is added and forms suspension, at room temperature stirring and crystallizing 1 day, mistake Filter, room temperature forced air drying 1 hour obtain 41mg his quinolines not moral alcohol solvent compound, yield 46%.

Embodiment 33

Taking his quinoline of 150mg preparation examples 1, moral is not placed in agate mortar, and 2mL ethyl alcohol is added, and is ground to dry, obtains 155mg His quinoline not moral alcohol solvent compound, yield 93%.

Embodiment 34

Taking his quinoline of 200mg preparation examples 1, moral is not placed in agate mortar, and 2mL ethyl alcohol is added, and is ground to dry, obtains 197mg His quinoline not moral alcohol solvent compound, yield 89%.

Embodiment 35

Taking his quinoline of 200mg preparation examples 1, Deping is not laid in culture dish, and culture dish is positioned over and closed is full of ethyl alcohol In the wide-mouth bottle of gas, 3 days are stood, obtains 220mg his quinolines not moral alcohol solvent compound, yield 99%.

Embodiment 36

Taking his quinoline of 50mg preparation examples 1, Deping is not laid in culture dish, and culture dish is positioned over and closed is full of ethanol gas In the wide-mouth bottle of body, 1 day is stood, obtains 55mg his quinolines not moral alcohol solvent compound, yield 99%.

Sample prepared by embodiment 26~36 with 25 sample of embodiment there is same or analogous XRPD collection of illustrative plates, PLM to scheme Spectrum, DSC collection of illustrative plates and TGA collection of illustrative plates (not shown).Illustrate that 26~36 sample of embodiment and 25 sample of embodiment are identical crystal forms.

Embodiment 37

His quinoline of 100mg preparation examples 1 not moral is taken, is dissolved with 5mL at 60 DEG C, with 10 DEG C/h of cooling speed under stirring Rate is down to 10 DEG C, precipitates crystal, filtering, room temperature forced air drying 2 hours, obtains 92mg his quinolines not Division A League Matches of Germany Football solvate A, yield It is as shown in figure 20 for 75%, XRPD collection of illustrative plates.

Embodiment 38

His quinoline of 100mg preparation examples 1 not moral is taken, is dissolved with 3.3mL toluene at 70 DEG C, with 30 DEG C/h under stirring Rate of temperature fall is down to -10 DEG C, precipitates crystal, filtering, room temperature forced air drying 2 hours, obtains 97mg his quinolines not Division A League Matches of Germany Football solvate B, yield 79%.XRPD collection of illustrative plates is as shown in figure 21.

Embodiment 39

Take his quinoline of 100mg preparation examples 1 not moral, dissolved with 2mL Isosorbide-5-Nitraes-dioxane at 60 DEG C, under stirring with 2 DEG C/it is small When rate of temperature fall be down to about 10 DEG C, precipitate crystal, filter, room temperature forced air drying 2 hours, obtain 88mg his quinolines not moral Isosorbide-5-Nitrae-two Six ring solvate B of oxygen, yield 72%.XRPD collection of illustrative plates is as shown in figure 16.

Embodiment 40

Take his quinoline of 100mg preparation examples 1 not moral, dissolved with 10mL Isosorbide-5-Nitraes-dioxane at 60 DEG C, under stirring with 20 DEG C/ Hour rate of temperature fall be down to about 10 DEG C, precipitate crystal, filter, room temperature forced air drying 2 hours, obtain 37mg his quinolines not moral Isosorbide-5-Nitrae- Dioxane solvent compound A, yield 30%.XRPD collection of illustrative plates is as shown in figure 15.

Embodiment 41

His quinoline of 200mg preparation examples 1 not moral is taken, the dissolving of 4mL methanol is added at 60 DEG C, under stiring with 10 DEG C/h Rate of temperature fall is down to about 10 DEG C, precipitates crystal, filtering, room temperature forced air drying half an hour, obtains 105mg his quinolines not Division A League Matches of Germany Football alcoholic solvent Compound, yield 49%, XRPD collection of illustrative plates are as shown in figure 18.

Embodiment 42

His quinoline of 160mg preparation examples 1 not moral is taken, is dissolved with 4mL isopropanols at 60 DEG C, under stiring with 10 DEG C/h Rate of temperature fall is down to about 10 DEG C, precipitates crystal, filtering, room temperature forced air drying 1 hour, obtains 157mg his quinolines not moral isopropanol solvent Compound, yield 86%, XRPD collection of illustrative plates are as shown in figure 19.

Embodiment 43

His quinoline of 100mg preparation examples 1 not moral is taken, is dissolved with 2mL tetrahydrofurans at 60 DEG C, under stiring with 10 DEG C/h Rate of temperature fall be down to about 10 DEG C, precipitate crystal, filter, room temperature forced air drying 1 hour, obtain 24mg his quinolines not moral tetrahydrofuran Solvate, yield 20%, XRPD collection of illustrative plates are as shown in figure 17.

Embodiment 44

His quinoline prepared by Example 9 his quinoline that not prepared by moral crystal form I, embodiment 25 not moral alcohol solvent compound, implement His quinoline prepared by example 41 his quinoline that not prepared by Division A League Matches of Germany Football solvate, embodiment 42 not moral isopropanol solvate, embodiment 39 His quinoline prepared his quinoline that not prepared by moral 1,4- dioxane solvents compound B, embodiment 43 not moral tetrahydrofuran solvate, His quinoline prepared by embodiment 37 his quinoline that not prepared by Division A League Matches of Germany Football solvate A and preparation example 1 not moral amorphous article, carries out HPLC Purity test the results are shown in Table 2.

2 comparison or purity table of table

Sample	HPLC purity
		His quinoline not moral amorphous article (preparation example 1)	96.27%
His quinoline not moral crystal form I (embodiment 9)	99.14%
		His quinoline not moral alcohol solvent compound (embodiment 25)	99.08%
His quinoline not Division A League Matches of Germany Football solvate (embodiment 41)	99.52%
		His quinoline not moral isopropanol solvate (embodiment 42)	99.84%
His quinoline not moral 1,4- dioxane solvents compound B (embodiment 39)	98.31%
		His quinoline not moral tetrahydrofuran solvate (embodiment 43)	98.03%
His quinoline not Division A League Matches of Germany Football solvate A (embodiment 37)	98.62%

2 result of table is shown：Using his quinoline, moral amorphous article does not prepare his quinoline to be formed not moral crystal form I, his quinoline not moral as raw material Alcohol solvent compound, his quinoline not Division A League Matches of Germany Football solvate, his quinoline not moral isopropanol solvate, his quinoline not moral 1,4- dioxies six Ring solvate B, his quinoline not moral tetrahydrofuran solvate, his quinoline not Division A League Matches of Germany Football solvate A, HPLC purity have compared with It is big to improve, reach higher than 98.0%, the HPLC purity of wherein his quinoline not moral crystal form I and his quinoline not moral alcohol solvent compound is high In 99.0%, especially formed his quinoline not Division A League Matches of Germany Football solvate or his quinoline not moral isopropanol solvate purification effect more To be apparent, HPLC purity is above 99.5%.

Embodiment 45

Take his quinoline prepared by preparation example 1 not moral amorphous article, the present invention his quinoline not moral crystal form I and his quinoline not moral ethyl alcohol Solvate, being at war with property experiment, examines or check its stability.The specific method is as follows：

(1) respectively taking his quinoline prepared by 20mg preparation examples 1, moral crystal form I is not mixed for moral amorphous article and his quinoline of the present invention Afterwards, it is added into 0.5mL water, forms suspension, be stirred at room temperature, sampling progress XRPD characterizations compare after 3 days.

(2) his quinoline not moral alcohol solvent of his quinoline prepared by 20mg preparation examples 1 not moral amorphous article and the present invention are respectively taken Object, after mixing, (volume ratio of water and ethyl alcohol is 1 to the mixed solvent of addition to 0.5mL water or 0.5mL water and ethyl alcohol:1~1:4) In, it is stirred at room temperature, sampling progress XRPD characterizations compare after 3 days.

As a result it shows：

(1) mixture containing his quinoline not his quinoline not moral crystal form I of moral amorphous article and the present invention is in water after magma 3 days, Detected through XRPD, his quinoline of transition cost invention not moral crystal form I, illustrate his quinoline of the present invention not moral crystal form I than it is known he Moral amorphous article does not have better stability to quinoline in water.

(2) mixture containing his quinoline not his quinoline not moral alcohol solvent compound of moral amorphous article and the present invention is in water or water (volume ratio of water and ethyl alcohol is 1 with the mixed solvent of ethyl alcohol:1~1:4) magma detected through XRPD, has been transformed into after 3 days in His quinoline of the present invention not moral alcohol solvent compound, illustrating his quinoline of the present invention, moral alcohol solvent compound is not than his known quinoline Moral amorphous article has better stability in water or water-ethanol system.

The above result shows that compared with his known quinoline not moral amorphous article, his of the invention quinoline not moral crystal form I and he Quinoline not in Aquo System more stablize by moral alcohol solvent compound, is more suitable for wet granulation.

Embodiment 46

The tablet of not moral crystal form I or his quinoline not moral alcohol solvent compound of his quinoline containing the present invention is prepared, specification is 0.5mg/ pieces (in terms of his quinoline not moral).Tablet formulation is shown in Table 3.

3 tablet formulation of table

Preparation process：

1：By his quinoline, moral alcohol solvent compound and microcrystalline cellulose are not adopted for moral crystal form I or his quinoline in three-dimensional mixer It is uniformly mixed with equivalent multiplication method, lactose, silica sieving mixing is added.

2：It will be mixed with mixture in step 1 after Magnesium Stearate.

3：By the mixture of step 2 in tabletted on rotary pelleting machine, totally 1000.

The above description is merely a specific embodiment, but scope of protection of the present invention is not limited thereto, appoints What those skilled in the art within the technical scope disclosed by the invention, the change that can be expected without creative work Change or replace, should be covered by the protection scope of the present invention.Therefore, protection scope of the present invention should be with claim Subject to protection domain defined by book.

All patent documents quoted in this specification are incorporated herein by way of quoting in its entirety.

Claims

1. his as follows quinoline of structural formula not moral alcohol solvent compound,

It is radiated using Cu-K α, moral alcohol solvent compound does not have his quinoline with the X-ray powder diffraction figure that 2 θ angles indicate Following characteristics peak：6.9 ± 0.2 °, 10.6 ± 0.2 °, 12.1 ± 0.2 °, 17.1 ± 0.2 °, 17.7 ± 0.2 ° and 21.2 ± 0.2 °.

2. his quinoline according to claim 1 not moral alcohol solvent compound, which is characterized in that his quinoline not moral alcohol solvent Compound has following characteristics peak with the X-ray powder diffraction figure that 2 θ angles indicate：6.9±0.2°、9.9±0.2°、10.6± 0.2°、12.1±0.2°、12.8±0.2°、16.3±0.2°、17.1±0.2°、17.7±0.2°、19.4±0.2°、21.2± 0.2 °, 22.6 ± 0.2 ° and 24.4 ± 0.2 °.

3. his quinoline not moral alcohol solvent compound according to claim 2, which is characterized in that his quinoline not moral alcohol solvent Object has following characteristics peak and its relative intensity with the X-ray powder diffraction figure that 2 θ angles indicate：

4. the preparation method of his quinoline according to any one of claims 1 to 3 not moral alcohol solvent compound, using following preparation sides Any one in method (1)~(6):

The ethanol solution that his quinoline not moral is formed at (1) 50 DEG C~70 DEG C, is cooled to -10 DEG C~10 DEG C by solution, precipitates crystal, obtain To his quinoline not moral alcohol solvent compound；

Preferably, the rate of the cooling is 2 DEG C/h~10 DEG C/h；

Preferably, a concentration of 40mg/mL~80mg/mL of described 50 DEG C~70 DEG C of his quinoline not moral ethanol solution；

(2) ethanol solution of his quinoline not moral is evaporated into dry, obtains his quinoline not moral alcohol solvent compound；

Preferably, the operation temperature of the preparation method (2) is room temperature；

(3) by his quinoline, moral is not dissolved in ethyl alcohol and forms solution, is added and is selected from water or C₆~C₈The anti-solvent of linear paraffin, stirring Crystallization obtains his quinoline not moral alcohol solvent compound；

Preferably, the anti-solvent is water or normal heptane；

Preferably, the volume ratio of the ethyl alcohol and anti-solvent is 1:1~1:4；

Preferably, the operation temperature of the preparation method (3) is room temperature；

Preferably, the time of the stirring and crystallizing is 0.5~10 hour；

Preferably, a concentration of 12.5mg/mL~25mg/mL of his quinoline not ethanol solution of moral；

(4) by his quinoline, moral does not form suspension in ethyl alcohol, stirring and crystallizing, obtains his quinoline not moral alcohol solvent compound；

Preferably, the operation temperature of the preparation method (4) is room temperature；

Preferably, the time of the stirring and crystallizing is 1 day~3 days；

Preferably, the w/v of moral and ethyl alcohol is not 50mg to his quinoline:1mL~80mg:1mL；

(5) it to the not German-Chinese addition ethyl alcohol of his quinoline, is ground to dry, obtains his quinoline not moral alcohol solvent compound；

Preferably, the w/v of moral and ethyl alcohol is not 75mg to his quinoline:1mL~100mg:1mL；

Preferably, the operation temperature of the preparation method (5) is room temperature；

(6) by his quinoline, moral is not statically placed in the closed environment full of alcohol gas, obtains his quinoline not moral alcohol solvent compound；

Preferably, the time of the standing is 1~3 day；

5. a kind of pharmaceutical composition, it includes treatment and/or prevention effective dose it is according to any one of claims 1 to 3 he Quinoline not moral alcohol solvent compound or preparation method obtains according to claim 4 his quinoline not moral alcohol solvent compound, and At least one pharmaceutically acceptable carrier or auxiliary agent.

6. his quinoline according to any one of claims 1 to 3 not moral alcohol solvent compound or the side of preparation according to claim 4 Moral alcohol solvent compound is not being prepared for treating and/or preventing malignant tumour, autoimmune disease or disease his quinoline that method obtains Manage the purposes in the drug of inflammatory disease；Wherein, the malignant tumour is selected from breast cancer, colon cancer, Kaposi's sarcoma, lung Cancer, oophoroma, prostate cancer and cutaneum carcinoma, the autoimmune disease be selected from multiple sclerosis, insulin-dependent diabetes mellitus, Systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and psoriasis, the pathology inflammatory disease are selected from asthma, move Pulse atherosclerosis, apoplexy and Alzheimer's disease.